GnRH receptor antagonist
Relugolix
Adult dose
Dose: Prostate cancer: 360mg PO loading day 1, then 120mg OD
Route: PO
Frequency: OD
Clinical pearls
- Advanced hormone-sensitive prostate cancer (oral alternative to LHRH analogues — no testosterone flare)
- Specialist initiation
Contraindications
- Severe hepatic impairment
- QT prolongation (caution)
- Concurrent strong P-gp inducers
Side effects
- Hot flushes
- Fatigue
- Reduced bone mineral density
- QT prolongation
- Hepatic transaminitis
Interactions
- P-gp/CYP3A4 modulators
- Hormonal therapies
Monitoring
- ECG
- BMD
- LFTs
- Testosterone
Reference: BNF; NICE TA832; SmPC; https://bnf.nice.org.uk/drugs/relugolix/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.